Every 424B that Jaguar Health, Inc. (JAGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow JAGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JAGX filings page.
Jaguar Health, Inc. (JAGX) updates its at-the-market equity program, stating that the aggregate offering price of common stock it may sell under its Form S-3 ATM facility has been reduced to approximately $4.78 million pursuant to General Instruction I.B.6 of Form S-3.
The company calculates the aggregate market value of common stock held by non-affiliates at about $14.99 million, based on 5,335,075 non-affiliate shares at $2.81 per share as of July 6, 2026, and notes that approximately $214,660 of stock has been sold under the I.B.6 limits in the prior 12-month period. Ladenburg Thalmann remains the sole sales agent under the ATM Agreement, and JAGX common stock trades on Nasdaq at a last reported price of $0.7299 per share on September 2, 2026.
Jaguar Health, Inc. (symbol JAGX) has filed a prospectus covering the potential resale by two selling stockholders of up to 40,874,552 shares of voting common stock. This consists of 40,000,000 Purchase Shares that may be issued under a June 9, 2026 equity line of credit with C/M Capital Master Fund, LP and 874,552 Commitment Shares (including shares issuable from pre-funded warrants) issued as consideration for that agreement. Jaguar is not selling any shares in this offering and will receive no proceeds from stockholder resales, but may sell shares directly to C/M Capital under the Purchase Agreement for up to $40 million in aggregate gross proceeds at discounted prices tied to market VWAP, subject to conditions, a 4.99% Beneficial Ownership Limitation, and a 19.99% Nasdaq stockholder-approval cap already obtained. Shares outstanding were 4,910,402 as of July 10, 2026; if all registered shares were issued and outstanding, they would exceed 89.3% of that baseline, highlighting substantial potential dilution.
Jaguar Health, Inc. is registering the potential resale of up to 5,483,086 shares of voting common stock for existing investors, not issuing new shares in this transaction and receiving no resale proceeds. These shares may be issued under a June 9, 2026 Series P Non-Convertible Preferred Stock financing and related pre-funded warrants, including up to 4,395,605 Redemption Shares, 32,535 Commencement Shares, and up to 1,054,946 Dividend Shares based on an 8% annual dividend over three years using a $0.546 Floor Price.
The preferred financing raised $2 million through 240 Series P shares with 8% dividends payable in cash or stock subject to an Equity Condition, and is linked to a $40 million equity line of credit with C/M Capital. As of July 10, 2026, common shares outstanding were 4,910,402; if all registered shares were issued, they would represent over 52.76% of the then-outstanding common stock, creating substantial dilution and potential selling pressure. The company also discloses restrictive covenants in the preferred agreements that can limit additional financings and details anti-takeover and capital structure terms.
Jaguar Health, Inc. registers up to 40,874,552 shares of common stock for resale by C/M Capital Master Fund, LP under a committed equity line of up to $40 million. Jaguar is not selling shares in this offering and will not receive proceeds from stockholder resales, though it may receive cash from future share sales to C/M Capital under the purchase agreement.
The equity line allows Jaguar, at its discretion and subject to conditions, to direct C/M Capital to buy shares through fixed and VWAP-based purchases, generally at a 5% discount to market, with a floor price of $1.10 and a 4.99% beneficial ownership cap. Shares outstanding were 4,910,402 as of July 10 2026; if all registered shares were issued, they would represent over 89% of that figure, materially diluting existing holders.
Jaguar intends to use any proceeds from sales to C/M Capital for working capital and general corporate purposes, including potential redemption of Series P Preferred Stock. The company also highlights extensive gastrointestinal drug-development programs centered on crofelemer, including orphan and rare disease indications such as MVID and SBS-IF.
Jaguar Health, Inc. is registering up to 2,621,852 shares of common stock for resale by existing investors. These shares include 1,980,827 shares issuable upon exchange of 950.8 outstanding shares of Series N Perpetual Preferred Stock, 161,583 PIPE shares, and 479,442 shares underlying a pre-funded warrant with a $0.0001 exercise price per share. The company will not receive proceeds from stockholder resales and would receive only about $48 if the pre-funded warrant is exercised for cash.
Jaguar is a commercial-stage pharmaceutical company focused on plant-based medicines for gastrointestinal disorders in people and animals. Its lead drug crofelemer underpins approved HIV-related diarrhea treatment Mytesi, a conditionally approved veterinary product for chemotherapy-induced diarrhea in dogs, and multiple late-stage and orphan programs, including cancer therapy-related diarrhea and rare diseases such as short bowel syndrome and microvillus inclusion disease. The company is also expanding into cancer supportive care with Gelclair and exploring CNS indications through its Magdalena joint venture.